Asia Pac ECM and Index Rebal, Shenton Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac ECM and Index Rebal

MINIMAX-W: Pre-Connect Inclusion Update and Positioning

MiniMax (00100 HK): AI Play with Net Cash, Connect Flows and the September Test

MiniMax (100 HK): 1H26 Preview, Robust Revenue with Both Tech Risk and Buying Opportunity

MINIMAX-W: P Removal Confirmed; HSCI / HK Connect Fast Entry Possible in June

Asia Pac IPO & Placement Research, China Biotech

DZT Research

DZT Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Equity Capital Markets

<ul>
<li>The 9 July wave. We detail the 153.5m-share six-month unlock, its holder composition, and the full cornerstone book.</li>
<li>Seller incentive. We assess how the share-price reset from the March peak changes holders' motivation to exit.</li>
<li>Positioning signals. We track token usage after the M3 launch, consensus revisions, and short positioning into the event.</li>
</ul>


The 9 July wave. We detail the 153.5m-share six-month unlock, its holder composition, and the full cornerstone book.
Seller incentive. We assess how the share-price reset from the March peak changes holders' motivation to exit.
Positioning signals. We track token usage after the M3 launch, consensus revisions, and short positioning into the event.


MINIMAX-W: Pre-Lock-Up Expiry Update, Positioning Revised